# Atrium Therapeutics, Inc. (RNA): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Atrium Therapeutics, Inc. (RNA) is 19/100, ranked against 24,000+ stocks in 35 markets (Quality 32, Value 37, Momentum 31, each scored against its sector).

- StockRank: 19/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 32, Value 37, Momentum 31: each a 0-100 percentile within Healthcare.
- Position: #21,472 overall, #1,943 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 8.05 USD on 26 Oct 2026.
- Insider filings, last 180 days: no director or 5%+ holder trades with a stated value.

Source: https://moatmap.ai/stock/RNA
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker